Challenges to breastfeeding infants with phenylketonuria
Sandra A Banta-Wright1, Sheila M Kodadek2, Robert D Steiner3
1School of Nursing, University of Washington, Seattle, WA.
Journal of Pediatric Nursing
|June 24, 2014
Summary
Mothers breastfeeding infants with phenylketonuria (PKU) face unique challenges, including frequent phenylalanine monitoring. Despite difficulties, many successfully adapt breastfeeding to manage Phe levels, though some encounter no issues.
Area of Science:
- Pediatrics
- Metabolic Disorders
- Lactation
Background:
- Infants with phenylketonuria (PKU) often have shorter breastfeeding durations compared to healthy full-term infants.
- Limited research exists on the specific breastfeeding challenges faced by mothers of infants with PKU.
Purpose of the Study:
- To identify and categorize the breastfeeding challenges encountered by mothers of infants with phenylketonuria (PKU).
Main Methods:
- A study involving 75 mothers of children diagnosed with PKU.
- Categorization of breastfeeding challenges into common issues, PKU-specific issues, and absence of challenges.
Main Results:
- Three main categories of breastfeeding challenges were identified: common breastfeeding problems, issues related to PKU management, and mothers reporting no challenges.
- Common breastfeeding issues were exacerbated by the necessity of frequent phenylalanine (Phe) monitoring in infants with PKU.
- Many mothers demonstrated adaptive strategies to maintain optimal Phe levels while breastfeeding.
Conclusions:
- Breastfeeding infants with PKU presents distinct challenges, primarily linked to metabolic monitoring.
- Maternal adaptation is key to successful breastfeeding in PKU management.
- While most mothers face hurdles, a minority report no breastfeeding difficulties.
More Related Videos
09:02Breast Milk Enhances Growth of Enteroids: An Ex Vivo Model of Cell Proliferation
Published on: February 15, 2018
18.7K
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
703
Related Concept Videos
01:20Inborn Errors of Metabolism
1.1K
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.1K
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
955
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
955
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
405
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
548
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
548
01:21Overview of Protein Metabolism
4.4K
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
4.4K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
401
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
401